None listed
Conditions
Brief summary
In this study we will compare the effects of fish oil (n=165) or placebo (n=165) in early infancy (from 0-6 months of age) on the risk of developing allergic sensitisation or allergic disease in early childhood. Both study groups will include children deemed to be at high risk of allergic disease (based on maternal allergy history).
Interventions
Children will be randomised to receive n-3 rich fish oil (280mg docosahexanoic acid [DHA]/day; 110mg eicosapentanoic acid [EPA]/day orally; Meg 3 Ocean Nutrition, Canada) daily for the first 6 months of life.
The capsules are identical in appearance. Peppermint flavour has been added to both fish oil and placebo capsules.
Sponsors
Prof Susan Prescott
Study design
Allocation
Randomised controlled trial
Intervention model
Single group
Primary purpose
Prevention
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No
Inclusion criteria
1) maternal asthma or hayfever, and atopy confirmed by skin testing (to common allergens); and 2) maternal age
Exclusion criteria
Infants will be excluded if: 1) their mother’s normal dietary intake exceeds 2 meals of fish per week 2) there are any significant pregnancy or neonatal complications including prematurity of < 36 weeks), or 3) parental smoking.
Outcome results
None listed